doubleblind
placebocontrol
studi
selfadminist
intranas
placebo
given
challeng
respiratori
syncyti
viru
incid
cold
sever
sign
symptom
reduc
receiv
compar
given
placebo
doubleblind
placebocontrol
studi
selfadminist
placebo
given
volunt
develop
cold
follow
challeng
respiratori
syncyti
viru
evid
reduc
sever
sign
symptom
shorten
durat
ill
similar
result
effect
rhinoviru
infect
volunt
discuss
respiratori
syncyti
viru
rsv
import
pathogen
particularli
infant
primari
infect
result
bronchiol
pneumonia
even
death
especi
prematur
babi
preexist
pulmonari
cardiac
abnorm
effect
vaccin
current
avail
ribavirin
therapi
shown
influenc
benefici
cours
diseas
costli
complic
administ
interferon
respons
rsv
infect
children
adult
minim
compar
influenza
viru
hall
et
al
mcintosh
isaac
hall
et
al
although
vitro
rsv
replic
readili
inhibit
interferon
moehr
forsyth
therefor
studi
prophylact
therapeut
effect
exogen
recombin
rsv
infect
adult
volunt
result
report
although
ill
follow
reinfect
rsv
adult
common
cold
differ
primari
infect
babi
affect
differ
region
respiratori
tract
result
obtain
could
give
indic
respons
expect
children
studi
approv
harrow
district
ethic
committe
northwick
park
healthi
volunt
age
year
recruit
hous
isol
common
cold
unit
group
two
three
accord
usual
practic
observ
daili
clinic
doubleblind
condit
symptom
sign
use
make
diagnosi
common
cold
construct
clinic
score
use
standard
paper
handkerchief
collect
weigh
give
daili
nasal
secret
weight
bear
reed
psycholog
score
extroversionintrovers
obsession
volunt
determin
influenc
clinic
virolog
respons
infect
totman
et
al
broadbent
et
al
lyophilis
roferona
roch
reconstitut
contain
million
unitsml
human
serum
albumin
phosphat
buffer
salin
constitut
placebo
interferon
placebo
prepar
fresh
altern
day
dispens
mistett
mark
ii
spray
deliv
ml
per
activ
viru
challeng
consist
bacteriolog
steril
tissu
cultur
fluid
strain
rsv
passag
contain
mckay
et
al
fail
produc
symptom
volunt
challeng
dose
chosen
repres
less
coldproduc
dose
viru
isol
inocul
nasal
wash
roller
tube
cultur
cell
presenc
anti
ifn
antiserum
unitsml
receiv
medic
unitsml
medic
ceas
viru
detect
identifi
specif
immunofluoresc
cell
scrape
tube
antivir
antibodi
detect
elisa
test
base
test
coronaviru
antibodi
previous
describ
callow
frozen
thaw
virusinfect
tissu
cultur
clarifi
centrifug
use
antigen
similarli
treat
uninfect
cultur
act
control
bound
directli
microtitr
plate
suitabl
dilut
serum
bound
igg
detect
phosphataselink
antibodi
probe
antibodi
titr
calcul
comput
programm
express
term
arbitrari
unit
assign
refer
human
serum
titrat
parallel
everi
set
assay
rise
repres
increas
twice
standard
error
test
regard
signific
antibodi
measur
way
good
predictor
suscept
infect
prophylact
trial
volunt
divid
two
group
balanc
age
sex
receiv
either
placebo
h
quarantin
period
volunt
selfadminist
supervis
ml
medic
nostril
three
time
day
dose
total
million
unit
four
hour
fourth
dose
medic
volunt
challeng
viru
salin
ml
nostril
volunt
assess
clinic
day
nasal
wash
viru
isol
collect
day
daili
day
inclus
volunt
request
suppli
convalesc
sampl
blood
therapeut
trial
h
quarantin
period
volunt
challeng
viru
salin
prophylact
studi
subject
diagnos
develop
cold
one
three
inspect
time
day
day
randomli
allot
receiv
placebo
ml
nostril
hourli
first
wake
hour
order
expos
mani
mucos
cell
possibl
soon
possibl
interferon
treatment
continu
four
time
day
three
day
end
trial
volunt
assess
clinic
nasal
wash
convalesc
blood
collect
prophylact
studi
statist
method
frequenc
cold
proport
volunt
infect
two
group
compar
test
signific
differ
clinic
score
nasal
secret
weight
determin
rank
analysi
varianc
block
effect
prechalleng
antibodi
titr
meddi
fortysix
volunt
enrol
prophylact
trial
three
exclud
either
develop
wild
cold
contact
one
two
fail
remain
full
length
trial
remain
took
part
studi
three
two
one
placebo
recipi
challeng
salin
two
group
well
balanc
sex
age
prechalleng
antibodi
concentr
psycholog
score
tabl
signific
differ
p
frequenc
cold
two
group
seven
cold
one
moder
six
mild
occur
volunt
receiv
placebo
compar
one
mild
cold
given
interferon
ten
group
show
laboratori
evid
infect
compar
placebo
group
mean
daili
clinic
score
fig
greater
day
group
placebo
group
howev
statist
signific
p
day
cold
appar
clinic
mean
daili
clinic
score
appreci
greater
placebo
group
reach
statist
signific
two
day
day
p
day
p
similar
pattern
seen
mean
daili
nasal
secret
weight
placebo
group
significantli
greater
group
three
day
day
p
day
p
mean
total
clinic
score
mean
total
nasal
secret
weight
placebo
group
significantli
greater
p
group
respect
cold
occur
among
three
salin
recipi
mean
total
clinic
score
mean
total
nasal
secret
weight
one
subject
given
placebo
g
respect
compar
g
two
receiv
sixti
volunt
enrol
therapeut
studi
one
exclud
result
medic
unfit
two
given
salin
challeng
rsv
develop
cold
eleven
volunt
cold
two
moder
nine
mild
given
placebo
three
moder
seven
iii
iii
iii
iii
v
mild
receiv
two
group
well
balanc
age
sex
psycholog
score
fig
sever
cold
onset
measur
mean
nasal
secret
weight
similar
progress
diseas
two
group
also
well
match
interv
onset
symptom
begin
treatment
signific
differ
two
group
increas
mean
clinic
score
interferon
group
day
p
pattern
viru
excret
also
similar
two
group
strike
featur
studi
similar
result
obtain
intranas
rhinoviru
infect
scott
et
al
scott
tyrrel
model
half
volunt
infect
viru
develop
cold
instanc
mark
prophylact
effect
evi
denc
benefici
action
given
therapeut
furthermor
signific
increas
mean
daili
clinic
score
group
compar
placebo
group
cold
develop
prophylact
studi
medic
therapeut
trial
provid
evid
interferon
given
even
short
period
act
irrit
hayden
et
al
scott
et
al
find
predict
rhinoviru
infect
direct
effect
viru
particl
requir
time
induc
antivir
state
host
cell
rsv
poor
induc
interferon
sensit
action
hope
might
possibl
use
interferon
treat
rsv
infect
evid
studi
support
therapeut
use
interferon
rsv
infect
although
still
possibl
interferon
might
effect
treat
primari
rsv
infect
infant
possibl
result
obtain
trial
similar
rhinoviru
infect
occur
clinic
ill
cold
site
infect
nose
nasopharynx
possibl
data
say
would
result
treat
bronchiol
intrapulmonari
howev
result
togeth
failur
system
interferon
influenc
cours
sever
rsv
infect
seven
children
chiba
et
al
offer
littl
encourag
hand
efficaci
prevent
rsv
infect
adult
suggest
contact
prophylaxi
studi
prevent
rsv
infect
children
high
risk
sever
infect
eg
babi
cystic
fibrosi
bronchopulmonari
dysplasia
analog
perform
hayden
et
al
dougla
et
al
rhinoviru
infect
might
effect
even
though
trend
studi
indic
benefici
effect
rsv
infect
